Cover Image
市場調查報告書

PARI Pharma GmbH:產品平台分析

PARI Pharma GmbH - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 226223
出版日期 內容資訊 英文 26 Pages
訂單完成後即時交付
價格
Back to Top
PARI Pharma GmbH:產品平台分析 PARI Pharma GmbH - Product Pipeline Review - 2014
出版日期: 2014年04月28日 內容資訊: 英文 26 Pages
簡介

PARI Pharma GmbH是利用eFlow及Vibrent技術等世界性高知名度氣霧遞送平台開發呼吸系統疾病用治療藥之製藥企業。

本報告提供PARI Pharma GmbH的治療藥開發平台現狀及各開發階段比較分析,為您彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

PARI Pharma GmbH的基本資料

PARI Pharma GmbH概要

  • 主要資訊
  • 企業資料

PARI Pharma GmbH:R&D概要

  • 主要的治療範圍

PARI Pharma GmbH:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

PARI Pharma GmbH:開發中產品概況

  • 後期開發中產品
    • 登記前的產品/聯合治療模式
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式

PARI Pharma GmbH:藥物簡介

  • tobramycin
  • cyclosporine liposomal
  • 呼吸疾病小分子

PARI Pharma GmbH:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

PARI Pharma GmbH:暫停中的計劃

PARI Pharma GmbH:總公司和子公司的所地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC04847CDB

Global Markets Direct's, 'PARI Pharma GmbH - Product Pipeline Review - 2014', provides an overview of the PARI Pharma GmbH's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of PARI Pharma GmbH's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of PARI Pharma GmbH including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of PARI Pharma GmbH's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the PARI Pharma GmbH's pipeline products

Reasons to buy

  • Evaluate PARI Pharma GmbH's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of PARI Pharma GmbH in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the PARI Pharma GmbH's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of PARI Pharma GmbH and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of PARI Pharma GmbH
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of PARI Pharma GmbH and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • PARI Pharma GmbH Snapshot
    • PARI Pharma GmbH Overview
    • Key Information
    • Key Facts
  • PARI Pharma GmbH - Research and Development Overview
    • Key Therapeutic Areas
  • PARI Pharma GmbH - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • PARI Pharma GmbH - Pipeline Products Glance
    • PARI Pharma GmbH - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • PARI Pharma GmbH - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
  • PARI Pharma GmbH - Drug Profiles
    • tobramycin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cyclosporine liposomal
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Respiratory Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • PARI Pharma GmbH - Pipeline Analysis
    • PARI Pharma GmbH - Pipeline Products by Target
    • PARI Pharma GmbH - Pipeline Products by Route of Administration
    • PARI Pharma GmbH - Pipeline Products by Molecule Type
    • PARI Pharma GmbH - Pipeline Products by Mechanism of Action
  • PARI Pharma GmbH - Dormant Projects
  • PARI Pharma GmbH - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • PARI Pharma GmbH, Key Information
  • PARI Pharma GmbH, Key Facts
  • PARI Pharma GmbH - Pipeline by Indication, 2014
  • PARI Pharma GmbH - Pipeline by Stage of Development, 2014
  • PARI Pharma GmbH - Monotherapy Products in Pipeline, 2014
  • PARI Pharma GmbH - Partnered Products in Pipeline, 2014
  • PARI Pharma GmbH - Partnered Products/ Combination Treatment Modalities, 2014
  • PARI Pharma GmbH - Pre-Registration, 2014
  • PARI Pharma GmbH - Phase III, 2014
  • PARI Pharma GmbH - Phase I, 2014
  • PARI Pharma GmbH - Pipeline by Target, 2014
  • PARI Pharma GmbH - Pipeline by Route of Administration, 2014
  • PARI Pharma GmbH - Pipeline by Molecule Type, 2014
  • PARI Pharma GmbH - Pipeline Products by Mechanism of Action, 2014
  • PARI Pharma GmbH - Dormant Developmental Projects,2014

List of Figures

  • PARI Pharma GmbH - Pipeline by Top 10 Indication, 2014
  • PARI Pharma GmbH - Pipeline by Stage of Development, 2014
  • PARI Pharma GmbH - Monotherapy Products in Pipeline, 2014
  • PARI Pharma GmbH - Pipeline by Top 10 Target, 2014
  • PARI Pharma GmbH - Pipeline by Top 10 Route of Administration, 2014
  • PARI Pharma GmbH - Pipeline by Top 10 Molecule Type, 2014
  • PARI Pharma GmbH - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top